^
    Back
    Association details:
    Biomarker:MGMT promoter methylation
    Cancer:Glioblastoma
    Drug:temozolomide (DNA synthesis inhibitor) +
    lomustine (Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: GLIOBLASTOMA….Adjuvant Treatment, KPS ≥60...Useful in Certain Circumstances...RT + concurrent and adjuvant lomustine and TMZ (for patients with MGMT promoter-methylated tumors and age ≤70 years) (category 2B).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

    Excerpt:
    ...Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin and eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status....
    Trial ID:
    NRG-BN011